|
The device return is anticipated; however, at the time of this report, the device has not been received by verathon.Verathon remains in contact with the canadian distributor and continues to investigate the reported event.A supplemental report will be submitted in accordance with 21 cfr 803.56 when additional information becomes available.
|
|
A facility reported that during an intubation attempt in the emergency department before surgery, using a glidescope spectrum single-use lopro s3 laryngoscope, the device's light source was dim and intermittently flickering on and off.Due to the reduced and inconsistent illumination, the clinician was unable to adequately visualize the airway, resulting in a prolonged intubation attempt.It was reported that the patient desaturated to 19% and experienced a loss of pulse.One round of cardiopulmonary resuscitation (cpr) was performed.A different glidescope system was obtained in an unspecified amount of time, and the airway was successfully secured on the second attempt.Patient demographic information and pre-existing medical conditions were declined to be provided by the facility upon request from verathon.
|
|
B4, g3, g6, h2, h6, h11
verathon's canadian distributor/importer reported on (b)(6), 2026 that the subject device return to verathon is anticipated and underway; however, at the time of this report, the device has not been received.Verathon notified the distributor on(b)(6), 2026 and (b)(6), 2026 informing them that the device was not yet received for evaluation.At this time, verathon does not expect the subject device to be returned to verathon for evaluation, therefore the cause of the reported issue could not be determined.Review of complaint history for the reported lot number "gt1013415" did not identify any previous complaints reported to verathon.Trending analysis for glidescope spectrum single-use lopro laryngoscopes does not identify any trends exceeding acceptable limits.Verathon confirmed that the risk associated with the hazardous scenario has been adequately captured and characterized per the system risk assessment.Should additional information become available, a supplemental report will be submitted in accordance with 21 cfr 803.56.Corrective action is not required at this time.Verathon will continue to monitor for trends.
|